NewsRelease
Cleanascite™Employed to Help Determine Role of Fatty Acids in MultipleMyeloma
MONMOUTHJUNCTION, NJ, June14, 2023 -- Biotech Support Group reports on an article, describingthe simplicity and efficiency of their lipid clearance samplepreparation technology to help determine the role of fatty acids inthe suppression of T cell function in the bone marrowmicroenvironment. The citation is:
Gudgeon,Nancy, et al. "Uptake of long-chain fatty acids from the bonemarrow suppresses CD8+ T-cell metabolism and function in multiplemyeloma." BloodAdvances (2023).
Tcells demonstrate impaired function in Multiple Myeloma (MM), butsuppressive mechanisms in the bone marrow (BM) microenvironmentremain poorly defined. In vitro modelling confirmed thatuptake of bone marrow lipids suppresses CD8 + T function, which isimpaired in autologous bone marrow plasma, but rescued by lipidremoval. The article states “…toprobe a role for lipids in this suppressive activity of BM plasma,they were depleted from BM samples (through the use of Cleanascite™)and compared with lipid-replete BM samples. Removal of BM lipidsincreased mitochondrial mass in control and MM BM CD8+ T cells(Figure 3E), accompanied by restoration of IFN-γ and TNF-αexpression (Figure 3F-H)..”.
Theauthors conclude that CD8+ 38 T-cell function andmitochondrial mass decline in the bone marrow in multiple myeloma andare lower than in matched peripheral blood. These changes are linkedto uptake of long-chain fatty acids and T-cell function and can berescued by blockade of the lipid transporter FATP1.
“Wenow have over twenty references, showing that Cleanascite™ was usedto help identify a characteristic feature of invitrocell response. Unlike alternative lipid-depletion methods that usesolvents, Cleanascite™ is an aqueous suspension product and so itis very compatible with cellular models of disease. This ultimatelyhelps with investigations such as this, whereby endogenous lipidsneed to be stripped to determine their influence on cell response.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Todownload whitepaper entitled “Cleanascite™- Lipid Removal and Cell Response Applications”,visit:
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal.From these innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com.
ForBusiness Development,contact:MatthewKuruc 732-274-2866, [email protected]